Annals

PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication

Retrieved on: 
Thursday, October 26, 2023
Spectrum, IBN, Manuscript, Health, Autism spectrum, MD, Psychiatry, Research, Evidence-based medicine, Suramin, Annals, ASD, Constance, Pharmaceutical industry

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (Nasdaq: PXMD ) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General Psychiatry, an internationally recognized scientific psychiatry publication, has accepted the manuscript titled "Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder" for publication.

Key Points: 
  • TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (Nasdaq: PXMD ) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General Psychiatry, an internationally recognized scientific psychiatry publication, has accepted the manuscript titled "Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder" for publication.
  • This groundbreaking research, authored by PaxMedica’s Chief Medical Officer, Dr. David Hough, MD, along with nine co-authors, highlights the potential of monthly suramin intravenous infusions as a safe and potentially efficacious treatment for the core symptoms of Autism Spectrum Disorder (ASD).
  • "The acceptance of this manuscript represents a significant milestone in PaxMedica's continued dedication to pioneering innovative treatments for Autism Spectrum Disorder.
  • As the manuscript progresses toward publication, PaxMedica extends its gratitude to the Annals of General Psychiatry for their support in sharing this essential research with the global scientific community.

Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023

Retrieved on: 
Monday, October 23, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Bevacizumab, Neoplasm, PRS, MTD, RAS, Annals of Oncology, ESMO, Principal investigator, Therapy, Assistant, Infrared spectroscopy correlation table, FOLFIRI, MOS, Congress, European Society for Medical Oncology, SLC6A8, BID, Rasm, HIV disease progression rates, Poster, BEV, CRC, Index, KOL, Cedars-Sinai Medical Center, ORR, RECIST, Annals, Apoptosis, Patient, Randomized controlled trial, Mutation, PR, Pharmaceutical industry, Medicine

The Phase 1b/2 study of ompenaclid in combination with FOLFIRI/BEV in second-line (2L) advanced or metastatic CRC patients has completed enrollment, with an ongoing follow up period.

Key Points: 
  • The Phase 1b/2 study of ompenaclid in combination with FOLFIRI/BEV in second-line (2L) advanced or metastatic CRC patients has completed enrollment, with an ongoing follow up period.
  • The primary endpoint of the study is to determine maximum tolerated dose (MTD), objective response rate (ORR), and treatment-emergent adverse events (TEAEs).
  • The abstract is published in the ESMO Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
  • Title: Phase 1b/2 study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)

Annals of Family Medicine: International Group of Research Experts Establish Checklist Detailing Key Consensus Reporting Items for Primary Care Studies

Retrieved on: 
Wednesday, October 4, 2023
Consensus, Annals of Family Medicine, Society, CRISP, College, Physician, Primary care, American Academy, North American Primary Care Research Group, Research, Multimedia, Delphi, American Board of Family Medicine, American Board of Commissioners for Foreign Missions, Literature, Family medicine, Guideline, Patient, College of Family Physicians of Canada, American Academy of Family Physicians, Teacher, Medical device, Nursing, Annals, Checklist

PROVIDENCE, R.I., Oct. 4, 2023 /PRNewswire/ -- An international group of leading primary care researchers has developed the first research reporting guideline for primary care: Consensus Reporting Items for Studies in Primary Care (CRISP) Checklist.

Key Points: 
  • PROVIDENCE, R.I., Oct. 4, 2023 /PRNewswire/ -- An international group of leading primary care researchers has developed the first research reporting guideline for primary care: Consensus Reporting Items for Studies in Primary Care (CRISP) Checklist.
  • Built by and for the international, interdisciplinary community, it addresses the unique perspectives, approaches and research concerns of primary care.
  • The special report is titled, "Improving the Reporting of Primary Care Research: Consensus Reporting Items for Studies in Primary Care - the CRISP Statement."
  • The CRISP Checklist outlines 24 items that describe the research team, patients, study participants, health conditions, clinical encounters, care teams, interventions, study measures, care settings, and implementation of findings/results in primary care.

Annals of Family Medicine: Researchers Describe Clinical Experiences of Transgender People, Recommend Strategies to Reduce Negative Health Consequences

Retrieved on: 
Monday, September 18, 2023
Medicalization, Annals of Family Medicine, Society, University, College, Physician, Curriculum, Empowerment, Yale Cancer Center, American Academy, North American Primary Care Research Group, Research, Multimedia, American Board of Family Medicine, American Board of Commissioners for Foreign Missions, Stigma, Family medicine, Patient, University of Rochester Medical Center, College of Family Physicians of Canada, American Academy of Family Physicians, Assault, Teacher, Safety, Nursing, Pharmaceutical industry, Annals

A new paper published in the September/October 2023 issue of Annals of Family Medicine describes the clinical experiences of transgender people.

Key Points: 
  • A new paper published in the September/October 2023 issue of Annals of Family Medicine describes the clinical experiences of transgender people.
  • Study authors also present short-term and long-term strategies towards reducing oppression and its health consequences among this patient population.
  • "Understanding the experiences of transgender people when their gender identities are known to clinicians and the reasons transgender people may share, modify, or withhold information could yield important clinical insights," the authors write.
  • Annals of Family Medicine is a peer-reviewed, indexed research journal that provides a cross-disciplinary forum for new, evidence-based information affecting the primary care disciplines.

Annals of Family Medicine: Papers illustrate ways in which federal and insurance policies may negatively influence primary care practice

Retrieved on: 
Tuesday, July 25, 2023
Vaccine, Workforce, Insurance, Annals of Family Medicine, Society, University, Public Service Loan Forgiveness, College, Private, Vaccination, ANN, NHSC, Physician, American Academy, North American Primary Care Research Group, Research, Multimedia, Family medicine, American Board of Family Medicine, Federally Qualified Health Center, American Board of Commissioners for Foreign Missions, Indian Health Service, Acquisition, Patient, University of Minnesota Medical School, Practitioner, College of Family Physicians of Canada, HPV, American Academy of Family Physicians, Health care, National Health Service Corps, American Association for Pediatric Ophthalmology and Strabismus, Forgiveness, Teacher, Pediatrics, Private sector, Nursing, Pharmaceutical industry, Doctor of Philosophy, Annals, PSLF

ANN ARBOR, Mich., July 25, 2023 /PRNewswire/ -- Two papers published in the July/August issue of Annals of Family Medicine address federal policy impact on Family Medicine practice.

Key Points: 
  • ANN ARBOR, Mich., July 25, 2023 /PRNewswire/ -- Two papers published in the July/August issue of Annals of Family Medicine address federal policy impact on Family Medicine practice.
  • The first documents differences in how federal medical school loan repayment programs support doctors who want to practice in rural and underserved areas.
  • The second describes the impact of differences in insurance reimbursement rates for identical care based on specialty and the implications of these differences on patient access to care.
  • Complete editorial content and interactive discussion groups for each published article can be accessed free of charge on the journal's website, www.AnnFamMed.org .

Together is the first app to use generative AI to make cumbersome healthcare tasks ‘magically easy’

Retrieved on: 
Tuesday, June 20, 2023
Apps, Applications, Technology, Mobile, Wireless, Health Technology, Telemedicine, Virtual Medicine, Software, Practice Management, Health, Artificial Intelligence, Blood pressure, IPhone, Experian, Google Play, Respiratory rate, Writing, Agency for Healthcare Research and Quality, Calendar, Ageing, Annals of Internal Medicine, Android, Multimedia, Quality, Ensuring Patient Access and Effective Drug Enforcement Act, Centers for Disease Control and Prevention, App Store (iOS/iPadOS), Annals, Patient, Agency, Internal medicine, Frustration, Apple, Conditional sentence, Heart rate, Health literacy, Caregiver, Medical device, Nursing, Health insurance

“As a practicing physician, every day I see patients and caregivers overwhelmed by follow-up steps, care plans and medications.

Key Points: 
  • “As a practicing physician, every day I see patients and caregivers overwhelmed by follow-up steps, care plans and medications.
  • Together makes otherwise cumbersome healthcare tasks magically easy, so people follow my care plans and actually achieve better outcomes," said Together by Renee co-founder and Chief Strategy Officer Dr. Renee Dua.
  • "In healthcare, the biggest impact on the most people comes from solving the most mundane problems," said Together by Renee co-founder and CEO Nick Desai.
  • “The 80 million Americans with more than two chronic conditions — myself included — consume 92% of the U.S. healthcare budget.

Caresyntax Announces Strategic Collaboration with ProAssurance to Offer Access to Cutting-Edge Surgical Intelligence to Data-Driven Surgeons

Retrieved on: 
Thursday, June 15, 2023
Software, General Health, Professional Services, Data Management, Technology, Medical Devices, Artificial Intelligence, Health Insurance, Data Analytics, Surgery, Audio, Video, Practice Management, Health, Partnership, Surgeon, Risk management, Intelligence, Organization, Medicare, ProAssurance, Agency for Healthcare Research and Quality, Annals, Hospital, Patient, Risk, Agency, PRA, ROI, NYSE, Dentistry

Caresyntax , the leading vendor-neutral enterprise surgical data and intelligence platform designed to make surgery smarter and safer, announced a strategic collaboration with ProAssurance Corporation (NYSE: PRA ), one of the nation's leading medical professional liability insurers, to provide innovative Caresyntax surgical intelligence tools to ProAssurance’s insured surgeons.

Key Points: 
  • Caresyntax , the leading vendor-neutral enterprise surgical data and intelligence platform designed to make surgery smarter and safer, announced a strategic collaboration with ProAssurance Corporation (NYSE: PRA ), one of the nation's leading medical professional liability insurers, to provide innovative Caresyntax surgical intelligence tools to ProAssurance’s insured surgeons.
  • Using Caresyntax’s transformational surgical intelligence platform, ProAssurance insured surgeons can integrate video and other real-world evidence from surgeries with data sets to provide insight into patient outcomes, operational efficiency, and profitability.
  • The enhanced capabilities through the surgical intelligence suite can help participating surgeons build a digital brand reputation for quality and create compelling patient education material using video and data.
  • This collaboration continues the historical trend of inventive alliances that both Caresyntax and ProAssurance have independently sought to drive improved outcomes and surgeon experience.

Annals of Family Medicine: Papers examine diet and clinical strategies that could help alleviate obesity, hypertension and diabetes in the United States

Retrieved on: 
Tuesday, May 23, 2023
Family medicine, Obesity, Diet, MyPlate, Calorie, ANN, Social support, Weight loss, Quality of life, Diabetes, Research, VLC, Hypertension, DASH, Annals, Waist, Satiation, Patient, Cooking, Physician, Risk, Standard of care, Overweight, Prediabetes, Hunger, Dietary supplement

The first of these studies compares two diets commonly used by physicians to support weight loss in patients -- MyPlate and the Diabetes Prevention Program Calorie Counting Diet. Findings suggest that the MyPlate diet, the federally-approved successor to the food pyramid, may lead to greater feelings of satiety, facilitating weight loss among patients.

Key Points: 
  • However, effective, evidence-based interventions for weight loss are not commonly delivered in the primary care context.
  • New research in the May/June 2023 issue of the Annals of Family Medicine sheds light on how primary care providers can more effectively treat patients living with obesity.
  • The first of these studies compares two diets commonly used by physicians to support weight loss in patients -- MyPlate and the Diabetes Prevention Program Calorie Counting Diet.
  • Findings suggest that the MyPlate diet, the federally-approved successor to the food pyramid, may lead to greater feelings of satiety, facilitating weight loss among patients.

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

Retrieved on: 
Wednesday, May 10, 2023
Molecular biology, The Elements of Style, Journal of Thoracic Oncology, Internet Technical Committee, Law, Lung cancer, Oncology, Article, Doctor of Philosophy, European Society for Medical Oncology, Audit committee, Teaching hospital, Professor, Retirement, Journal, University Hospital (Newark, New Jersey), Ageing, Health, Ludwig Cancer Research, Annals of Oncology, Swiss, SIX Swiss Exchange, Teaching, International Association, Research, Attention, Annals, Security (finance), Editor-in-chief, Woman, Swiss Federal Institute of Technology, ESMO, Medicine, NSCLC, US, HKEX, Letter, Swiss Federal Institute of Aquatic Science and Technology, Part, University of Lausanne, Galenica, Strategic Advisory Board for Intellectual Property Policy, HK, Management, Nursing

The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.

Key Points: 
  • The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.
  • Mr Simon To, Chairman of HUTCHMED said “On behalf of the Board, I would like to extend a warm welcome to Professor Peters to the Company.
  • Professor Peters is also an independent director of Galenica AG, which is listed on the SIX Swiss Exchange.
  • The director’s fees of Professor Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company under her appointment letter are US$76,000, US$8,000 and US$13,500 per annum respectively.

Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome

Retrieved on: 
Tuesday, April 4, 2023
Medical Affairs Bureau, Research and development, Swedish Orphan Biovitrum, Pediatrics, Glucocorticoid, Emapalumab, Macrophage, Annals of the Rheumatic Diseases, HLH, MAS, Cincinnati Children's Hospital Medical Center, AOSD, Tocilizumab, Development, Annals, Patient, Division, Bambino, Hospital, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Laboratory, Food, Safety, Disease, Pharmaceutical industry, Rheumatology

In the published study, 14 patients with sJIA or AOSD and sHLH/MAS who did not respond to high-dose glucocorticosteroids received emapalumab.

Key Points: 
  • In the published study, 14 patients with sJIA or AOSD and sHLH/MAS who did not respond to high-dose glucocorticosteroids received emapalumab.
  • All 14 patients completed the trial, entered long-term follow-up and were alive at the end of follow-up.
  • Based on the results of this study, Sobi decided to continue to evaluate emapalumab in this patient population and initiated the EMERALD phase 3 study, which is ongoing.
  • “We remain committed to evaluating emapalumab as a potential new treatment option for patients affected by this severe condition.